273 related articles for article (PubMed ID: 32260160)
1. Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
Yen JH; Lin CY; Chuang CH; Chin HK; Wu MJ; Chen PY
Cells; 2020 Apr; 9(4):. PubMed ID: 32260160
[TBL] [Abstract][Full Text] [Related]
2. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3.
Tringali C; Lupo B; Cirillo F; Papini N; Anastasia L; Lamorte G; Colombi P; Bresciani R; Monti E; Tettamanti G; Venerando B
Cell Death Differ; 2009 Jan; 16(1):164-74. PubMed ID: 18820643
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.
Dorsey JF; Cunnick JM; Mane SM; Wu J
Blood; 2002 Feb; 99(4):1388-97. PubMed ID: 11830491
[TBL] [Abstract][Full Text] [Related]
4. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
5. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
7. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
Yang Y; Liu X; Xiao F; Xue S; Xu Q; Yin Y; Sun H; Xu J; Wang H; Zhang Q; Wang H; Wang L
PLoS One; 2015; 10(2):e0117573. PubMed ID: 25688862
[TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.
Pettiford SM; Herbst R
Leukemia; 2003 Feb; 17(2):366-78. PubMed ID: 12592337
[TBL] [Abstract][Full Text] [Related]
9. 5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF-κB/TNF-α Pathway and Exerts Antileukemic Effects in AML Cells.
Chen PY; Wang CY; Tsao EC; Chen YT; Wu MJ; Ho CT; Yen JH
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806401
[TBL] [Abstract][Full Text] [Related]
10. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
[TBL] [Abstract][Full Text] [Related]
11. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
12. ZNF300 knockdown inhibits forced megakaryocytic differentiation by phorbol and erythrocytic differentiation by arabinofuranosyl cytidine in K562 cells.
Cai J; Gong R; Yan F; Yu C; Liu L; Wang W; Lin Y; Guo M; Li W; Huang Z
PLoS One; 2014; 9(12):e114768. PubMed ID: 25485965
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
14. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
15. A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
Turroni S; Tolomeo M; Mamone G; Picariello G; Giacomini E; Brigidi P; Roberti M; Grimaudo S; Pipitone RM; Di Cristina A; Recanatini M
PLoS One; 2013; 8(2):e57650. PubMed ID: 23460890
[TBL] [Abstract][Full Text] [Related]
16. Induction of megakaryocytic differentiation in chronic myelogenous leukemia cell K562 by 3-hydrogenkwadaphnin.
Meshkini A; Yazdanparast R
J Biochem Mol Biol; 2007 Nov; 40(6):944-51. PubMed ID: 18047790
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.
Eskandari S; Yazdanparast R
J Cell Biochem; 2019 Jun; 120(6):10128-10136. PubMed ID: 30548309
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
19. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
Huang YW; Lee WH; Tsai YH; Huang HM
Am J Physiol Cell Physiol; 2014 Jan; 306(1):C37-44. PubMed ID: 24088895
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
